Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 11/20 | 0.53 |
| ▸ | TDP2 | O95551 | 1/20 | 0.45 |
| ▸ | JAK2 | O60674 | 4/20 | 0.43 |
| ▸ | JAK1 | P23458 | 4/20 | 0.43 |
| ▸ | JAK3 | P52333 | 4/20 | 0.43 |
| ▸ | TYK2 | P29597 | 3/20 | 0.43 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
| ▸ | NUAK2 | Q9H093 | 1/20 | 0.41 |
| ▸ | BMP2K | Q9NSY1 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL240475 | 0.91 | TDP1 (0.49) | TDP1TDP2JAK2JAK1JAK3 | |
| SCHEMBL19456961 | 0.91 | TDP1 (0.54) | TDP1TDP2JAK2JAK1JAK3 | |
| SCHEMBL4988592 | 0.89 | TDP1 (0.52) | TDP1TDP2JAK2JAK1JAK3 | |
| SCHEMBL4984289 | 0.89 | TDP1 (0.51) | TDP1TDP2JAK2JAK1JAK3 | |
| SCHEMBL29360706 | 0.88 | TDP1 (0.69) | TDP1TDP2JAK2JAK1JAK3 | |
| Genz-644282 SCHEMBL241696 | 0.88 | TDP1 (0.52) | TDP1TDP2JAK2JAK1JAK3 | |
| Genz-644282 SCHEMBL29632787 | 0.88 | TDP1 (0.52) | TDP1TDP2JAK2JAK1JAK3 | |
| SCHEMBL241242 | 0.88 | TDP1 (0.69) | TDP1TDP2JAK2JAK1JAK3 | |
| SCHEMBL241732 | 0.87 | TDP1 (0.51) | TDP1JAK2JAK1JAK3TYK2 | |
| SCHEMBL5016835 | 0.87 | TDP1 (0.52) | TDP1TDP2JAK2JAK1JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012015875-A1 | METHODS FOR TREATING HEMATOLOGICAL MALIGNANCIES | GENZYME CORPORATION (US) | 2012-02-02 | — | — | WO | claimed |
| US-20120004235-A1 | METHODS TO TREAT CANCER | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2012-01-05 | — | — | US | claimed |
| US-7781587-B2 | antitumor; breast cancer; 8,9-Dimethoxy-2,3-methylenedioxy-5-[2-(N,N-dimethylamino)ethyl]-5H-dibenzo[c,h]1,6-naphthyridin-6-one | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2010-08-24 | — | — | US | claimed |
| WO-2010088544-A1 | METHODS TO TREAT CANCER | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2010-08-05 | — | — | WO | claimed |
| US-20090239871-A1 | SOLUBILIZED TOPOISOMERASE POISONS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2009-09-24 | — | — | US | claimed |
| US-8389721-B2 | Solubilized topoisomerase poisons | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2013-03-05 | — | — | US | disclosed |
| WO-2012015875-A1 | METHODS FOR TREATING HEMATOLOGICAL MALIGNANCIES | GENZYME CORPORATION (US) | 2012-02-02 | — | — | WO | disclosed |
| US-20120004235-A1 | METHODS TO TREAT CANCER | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2012-01-05 | — | — | US | disclosed |
| US-20110136812-A1 | SOLUBILIZED TOPOISOMERASE POISONS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2011-06-09 | — | — | US | disclosed |
| EP-2286812-A1 | Solubilized topoisomerase poisons | Rutgers, The State University (US) | 2011-02-23 | — | — | EP | disclosed |
| US-7781587-B2 | antitumor; breast cancer; 8,9-Dimethoxy-2,3-methylenedioxy-5-[2-(N,N-dimethylamino)ethyl]-5H-dibenzo[c,h]1,6-naphthyridin-6-one | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2010-08-24 | — | — | US | disclosed |
| EP-2196205-A1 | Topoisomerase poisons | Rutgers, The State University (US) | 2010-06-16 | — | — | EP | disclosed |
| EP-1465625-B1 | SOLUBILIZED TOPOISOMERASE POISONS | UNIV RUTGERS (US) | 2010-02-03 | — | — | EP | disclosed |
| US-20090239871-A1 | SOLUBILIZED TOPOISOMERASE POISONS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2009-09-24 | — | — | US | disclosed |
| US-7517883-B2 | Solubilized topoisomerase poisons | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2009-04-14 | — | — | US | disclosed |
| US-7049315-B2 | Solubilized topoisomerase poisons | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2006-05-23 | — | — | US | disclosed |
| US-20060052381-A1 | Solubilized topoisomerase poisons | LAVOIE EDMOND J | 2006-03-09 | — | — | US | disclosed |
| US-20050009824-A1 | Solubilized topoisomerase poisons | RUTGERS, STATE UNIVERSITY OF NEW JERSEY, THE | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009824-A1 | Solubilized topoisomerase poisons | TOP1, TOP2A, TOP2B | TDP1 4/4885TDP2 8/4885JAK2 4385/4885 |
| US-20090239871-A1 | SOLUBILIZED TOPOISOMERASE POISONS | TOP1, TOP2A, TOP2B | TDP1 4/4885TDP2 8/4885JAK2 4385/4885 |
| US-20120004235-A1 | METHODS TO TREAT CANCER | TP53, CCNY, ABCB1 | TDP1 2248/4885TDP2 2459/4885JAK2 411/4885 |
| US-20110136812-A1 | SOLUBILIZED TOPOISOMERASE POISONS | TOP1, TOP2A, TOP2B | TDP1 4/4885TDP2 8/4885JAK2 4385/4885 |
| US-20060052381-A1 | Solubilized topoisomerase poisons | TOP1, TOP2A, TOP2B | TDP1 4/4885TDP2 8/4885JAK2 4385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.